question_id,date,category,question_text,baseline_success,baseline_actually_answered,baseline_has_expected,baseline_confidence,baseline_text,baseline_error,baseline_time,baseline_input_tokens,baseline_output_tokens,togomcp_success,togomcp_has_expected,togomcp_confidence,togomcp_text,togomcp_error,togomcp_time,togomcp_input_tokens,togomcp_output_tokens,togomcp_cache_creation_input_tokens,togomcp_cache_read_input_tokens,tools_used,tool_details,value_add,expected_answer,notes
85,2026-01-31,Structured Query,What reactions convert ATP to ADP during phosphate transfer?,True,True,True,0.6666666666666666,"ATP is converted to ADP during phosphate transfer through **phosphorylation reactions** (also called **phosphoryl transfer reactions**). Here are the main types:

## 1. **Substrate-Level Phosphorylation**
Direct transfer of a phosphate group from ATP to a substrate molecule:
- **Kinase reactions** - enzymes called kinases catalyze phosphate transfer to various molecules
- Example: Hexokinase transfers phosphate from ATP to glucose, forming glucose-6-phosphate + ADP

## 2. **Protein Phosphorylation**
Transfer of phosphate to proteins for regulatory purposes:
- Protein kinases phosphorylate serine, threonine, or tyrosine residues
- Example: Protein kinase A (PKA) phosphorylates target proteins in signaling cascades

## 3. **Coupled Reactions**
ATP hydrolysis coupled to energy-requiring processes:
- **Motor proteins** (myosin, kinesin) - ATP → ADP powers movement
- **Active transport pumps** (Na⁺/K⁺-ATPase) - uses ATP → ADP to pump ions against gradients
- **DNA/RNA synthesis** - though these use ATP → AMP + PPi primarily

## General Mechanism
The typical reaction is:
**ATP + Substrate → ADP + Phosphorylated-Substrate**

The terminal (gamma) phosphate of ATP is transferred, leaving ADP. This reaction is thermodynamically favorable (releases energy) and is used to drive otherwise unfavorable cellular processes.

These reactions are fundamental to metabolism, cell signaling, biosynthesis, and mechanical work in cells.",,9.91650390625,49,383,True,True,0.6666666666666666,"Based on my search of the Rhea biochemical reactions database, I found numerous reactions that convert ATP to ADP during phosphate transfer. These reactions fall into several major categories:

## Main Types of ATP → ADP Phosphate Transfer Reactions:

### 1. **Protein Phosphorylation (Kinases)**
These reactions phosphorylate amino acid residues on proteins:
- **Serine phosphorylation**: e.g., RHEA:18673 - phosphorylation of receptor proteins
- **Threonine phosphorylation**: e.g., RHEA:11424 - phosphorylation of myosin heavy chain
- **Histidine phosphorylation**: e.g., RHEA:11860 - phosphorylation of histidyl-proteins
- **Tyrosine phosphorylation**: Various protein kinase reactions

### 2. **Nucleotide Phosphorylation**
ATP phosphorylates nucleotide monophosphates to diphosphates:
- **RHEA:12973**: AMP + ATP → 2 ADP (adenylate kinase)
- **RHEA:11600**: CMP + ATP → CDP + ADP
- **RHEA:20780**: GMP + ATP → GDP + ADP
- **RHEA:12697**: dGMP + ATP → dGDP + ADP
- **RHEA:13517**: dTMP + ATP → dTDP + ADP

### 3. **Nucleoside Phosphorylation**
Converting nucleosides to nucleotide monophosphates:
- **RHEA:20824**: adenosine + ATP → AMP + ADP
- **RHEA:16825**: uridine + ATP → UMP + ADP
- **RHEA:19129**: thymidine + ATP → dTMP + ADP
- **RHEA:19201**: 2'-deoxyguanosine + ATP → dGMP + ADP

### 4. **Lipid Phosphorylation**
Phosphorylating various lipids:
- **RHEA:10272**: diacylglycerol → phosphatidate (diacylglycerol kinase)
- **RHEA:12280**: PI5P → PIP2 (phosphoinositide kinases)
- **RHEA:21292**: PIP2 → PIP3 (PI3-kinase reaction)

### 5. **Inositol Phosphate Phosphorylation**
Multiple reactions adding phosphates to inositol derivatives:
- **RHEA:11020**: IP3 → IP4
- **RHEA:20313**: IP5 → IP6 (phytic acid synthesis)

These are all examples of **kinase reactions** where ATP serves as the phosphate donor, transferring its terminal (gamma) phosphate to a substrate molecule, producing ADP and the phosphorylated product. This is one of the most fundamental energy-coupling mechanisms in biochemistry.",,45.931636095047,23,1107,3976,135994,"mcp__togomcp__search_rhea_entity, mcp__togomcp__search_rhea_entity, mcp__togomcp__search_rhea_entity, mcp__togomcp__search_rhea_entity","[{""name"": ""mcp__togomcp__search_rhea_entity"", ""input"": {""query"": ""ATP ADP phosphate transfer"", ""limit"": 50}}, {""name"": ""mcp__togomcp__search_rhea_entity"", ""input"": {""query"": ""ATP = ADP + phosphate"", ""limit"": 50}}, {""name"": ""mcp__togomcp__search_rhea_entity"", ""input"": {""query"": ""ATP ADP kinase"", ""limit"": 50}}, {""name"": ""mcp__togomcp__search_rhea_entity"", ""input"": {""query"": ""ATP phosphorylation"", ""limit"": 50}}]",VALUABLE,Kinase reactions that consume ATP and produce ADP during phosphoryl group transfer,"COMPLEX QUERY requiring compound-product relationship knowledge.

Databases/Resources: Rhea, ChEBI

Knowledge Required:
- Boolean bif:contains: ""('ATP' AND 'ADP')""
- Reaction-side relationship for substrate vs product
- rhea:status rhea:Approved filter
- Relevance scoring option

Without proper knowledge: Cannot properly search for compound pairs in reactions.

Verified in rhea_exploration.md Pattern 6."
86,2026-01-31,Structured Query,Find all subtypes of autophagy in Gene Ontology including their specific functions.,True,True,True,0.7857142857142857,"# Subtypes of Autophagy in Gene Ontology

Based on Gene Ontology classifications, here are the major subtypes of autophagy and their specific functions:

## 1. **Macroautophagy**
- Most well-characterized form
- Involves formation of double-membrane vesicles (autophagosomes) that engulf cytoplasmic cargo
- Delivers contents to lysosomes/vacuoles for degradation
- Functions in bulk degradation of proteins and organelles

## 2. **Microautophagy**
- Direct engulfment of cytoplasmic material by lysosome/vacuole membrane invagination
- No autophagosome formation required
- Functions in selective or non-selective degradation

## 3. **Chaperone-Mediated Autophagy (CMA)**
- Selective process requiring chaperone proteins (HSC70)
- Recognizes proteins with KFERQ-like motifs
- Direct translocation across lysosomal membrane via LAMP2A receptor
- Functions in selective protein degradation

## 4. **Selective Autophagy Subtypes**

### **Mitophagy**
- Selective degradation of mitochondria
- Removes damaged or excess mitochondria
- Critical for mitochondrial quality control

### **Pexophagy**
- Selective degradation of peroxisomes
- Regulates peroxisome number and turnover

### **Reticulophagy (ER-phagy)**
- Selective degradation of endoplasmic reticulum
- Maintains ER homeostasis and quality control

### **Ribophagy**
- Selective degradation of ribosomes
- Regulates ribosome turnover

### **Xenophagy**
- Selective degradation of intracellular pathogens (bacteria, viruses)
- Part of innate immunity

### **Aggrephagy**
- Selective degradation of protein aggregates
- Important for proteostasis

### **Lipophagy**
- Selective degradation of lipid droplets
- Regulates lipid metabolism

### **Nucleophagy**
- Selective degradation of nuclear components
- Including piecemeal microautophagy of the nucleus (PMN)

### **Lysophagy**
- Selective degradation of damaged lysosomes
- Lysosomal quality control

## General Functions Across Subtypes:
- Cellular homeostasis and quality control
- Stress response and adaptation
- Development and differentiation
- Nutrient recycling during starvation
- Immune defense
- Prevention of neurodegeneration and other diseases

These classifications represent the GO hierarchical organization of autophagy processes based on mechanism and cargo specificity.",,12.31728219985962,55,649,True,True,0.6428571428571429,"Perfect! Now I have comprehensive information about all subtypes of autophagy in Gene Ontology. Let me compile this into a clear and organized summary for you.

## Autophagy Subtypes in Gene Ontology

Based on the Gene Ontology database, autophagy (GO:0006914) has multiple distinct subtypes, each with specialized functions. Here's a comprehensive overview:

### **Main Categories of Autophagy**

#### **1. Macroautophagy (GO:0016236)**
The autophagic process that proceeds via the formation of an autophagosome (a double-membrane vesicle).

**Specialized Macroautophagy Subtypes:**

- **Mitophagy (GO:0000423)** - Selective degradation of mitochondria
  - *Type 1 Mitophagy (GO:0180045)* - Degradation of functional mitochondria during nutrient deprivation or to remove excess mitochondria
  - *Type 2 Mitophagy (GO:0061734)* - Degradation of damaged/dysfunctional mitochondria initiated by depolarization and Parkin binding

- **Pexophagy (GO:0000425)** - Selective degradation of peroxisomes

- **Reticulophagy (GO:0061709)** - Selective degradation of endoplasmic reticulum parts

- **Ribophagy (GO:0034517)** - Selective degradation of mature ribosomes

- **Lipophagy (GO:0061724)** - Selective degradation of lipid droplets

- **Glycophagy (GO:0061723)** - Selective degradation of glycogen

- **Aggrephagy (GO:0035973)** - Selective degradation of protein aggregates

- **Nucleophagy (GO:0044804)** - Degradation of damaged or non-essential parts of the nucleus

- **Xenophagy (GO:0098792)** - Selective degradation of intracellular pathogens (e.g., bacteria, viral capsids)

- **Lysophagy (GO:0062093)** - Selective degradation of damaged lysosomes

- **Proteaphagy (GO:0061816)** - Selective degradation of proteasomes

#### **2. Microautophagy (GO:0016237)**
Autophagy where cytosolic components are directly engulfed by lysosomes/vacuoles through membrane invagination, without forming an autophagosome first.

**Microautophagy Subtypes:**

- **Micropexophagy (GO:0000426)** - Degradation of peroxisomes by microautophagy

- **Micromitophagy (GO:0000424)** - Degradation of mitochondria by microautophagy

- **Piecemeal Microautophagy of the Nucleus (GO:0034727)** - Degradation of nuclear components by microautophagy

- **Late Endosomal Microautophagy (GO:0061738)** - Chaperone-tagged proteins are directly transferred into and degraded in late endosomes

- **Microlipophagy (GO:0140504)** - Degradation of lipid droplets by microautophagy

#### **3. Chaperone-Mediated Autophagy (GO:0061684)**
Process where chaperones recognize a target motif, unfold substrate proteins, and transport them to lysosomes for degradation (no vesicle formation).

#### **4. Other Specialized Types:**

- **Crinophagy (GO:0160155)** - Direct fusion of abnormal, excess, or obsolete secretory granules with lysosomes; maintains homeostasis in endocrine and exocrine cells

- **Mitophagy by Internal Vacuole Formation (GO:0035695)** - Mitochondria are directly engulfed by lysosome-like vacuoles (distinct from canonical autophagy)

### **Key Functional Distinctions**

1. **Nutrient Response**: Types like Type 1 mitophagy and glycophagy provide metabolic precursors during starvation

2. **Quality Control**: Type 2 mitophagy, lysophagy, and aggrephagy remove damaged or dysfunctional cellular components

3. **Pathogen Defense**: Xenophagy eliminates intracellular pathogens

4. **Homeostasis**: Crinophagy maintains proper levels of secretory granules

5. **Metabolic Regulation**: Lipophagy and glycophagy regulate energy storage and utilization

This hierarchical organization reflects the diverse cellular needs for selective degradation and recycling of specific cellular components through autophagy mechanisms.",,38.84799885749817,12,1442,51196,113281,"mcp__ols__searchClasses, mcp__ols__getDescendants","[{""name"": ""mcp__ols__searchClasses"", ""input"": {""query"": ""autophagy"", ""ontologyId"": ""go"", ""pageSize"": 50}}, {""name"": ""mcp__ols__getDescendants"", ""input"": {""ontologyId"": ""go"", ""classIri"": ""http://purl.obolibrary.org/obo/GO_0006914"", ""pageSize"": 100}}]",VALUABLE,"25 descendant terms including macroautophagy, microautophagy, mitophagy, chaperone-mediated autophagy, and other autophagy subtypes with their definitions","COMPLEX QUERY requiring hierarchical ontology navigation and property retrieval.

Databases/Resources: GO

Knowledge Required:
- rdfs:subClassOf traversal for hierarchy
- FROM clause for consistent results
- Property retrieval for definitions and labels
- STRSTARTS filter for GO URI identification

Without proper knowledge: Missing FROM clause causes duplicated/inconsistent results.

Verified in go_exploration.md Pattern 2 and Pattern 6."
87,2026-01-31,Integration,What proteins have both PDB structures and involvement in autophagy pathways?,True,True,True,0.6,"Based on my training knowledge, here are some key proteins that have both PDB structures and documented roles in autophagy pathways:

## Core Autophagy Machinery (ATG proteins)

**LC3/ATG8 family:**
- LC3B (MAP1LC3B) - Multiple PDB structures available (e.g., 1UGM, 1V49)
- GABARAP family members - Several structures deposited

**ATG12-ATG5 conjugation system:**
- ATG12 - Structures available
- ATG5 - Structures available, including ATG12-ATG5 conjugate
- ATG16L1 - Structures of domains available

**ATG4 (proteases):**
- ATG4B - Multiple structures (e.g., 2CY7, 2D1I)
- Critical for LC3 processing

**ATG7 and ATG3:**
- Both E1-like and E2-like enzymes with solved structures
- Essential for ubiquitin-like conjugation in autophagy

## Regulatory Proteins

**mTOR complex:**
- mTOR kinase - Structures available
- Central negative regulator of autophagy

**ULK1/ATG1 complex:**
- ULK1 kinase domain structures
- Initiates autophagosome formation

**Beclin-1 complex components:**
- VPS34 (PI3KC3) - Structures available
- Beclin-1 domains
- ATG14L

**SQSTM1/p62:**
- Autophagy receptor with multiple PDB structures
- Contains UBA and LIR domains

These proteins are well-characterized structurally and functionally in autophagy research.",,10.303159713745117,53,413,True,True,0.8,"Based on my search of biological databases, I found numerous proteins that have both PDB structures and involvement in autophagy pathways. Here are the key findings:

## Core Autophagy Proteins with PDB Structures

### **ATG Family Proteins:**

1. **LC3/GABARAP Family** (ATG8 homologs)
   - **LC3A, LC3B, LC3C** - Microtubule-associated protein 1 light chain 3
   - **GABARAP, GABARAPL1, GABARAPL2** - GABA receptor-associated proteins
   - PDB examples: 2NCN (LC3C), 1KOT (GABARAP), 8T35 (LC3A), 3X0W (LC3B)
   - These are essential for autophagosome formation and cargo recognition

2. **ATG4 Proteases** (ATG4A, ATG4B, ATG4C, ATG4D)
   - Cysteine proteases that process ATG8 family proteins
   - PDB examples: 2P82 (ATG4A), 2CY7, 2D1I, 2Z0D (ATG4B)
   - UniProt: Q8WYN0 (ATG4A), Q9Y4P1 (ATG4B)

3. **ATG5-ATG12-ATG16L1 Complex**
   - Essential E3-like enzyme complex for LC3 lipidation
   - PDB examples: 4GDK, 4GDL (ATG5-ATG12-ATG16L1 complex), 4TQ0 (ATG5-ATG16)
   - UniProt: Q9H1Y0 (ATG5), O94817 (ATG12)

4. **ATG3 and ATG7**
   - E2-like and E1-like enzymes in ubiquitin-like conjugation systems
   - PDB examples: 3T7E-3T7H (ATG7-ATG8-ATG3 complexes)
   - UniProt: Q9NT62 (ATG3), O95352 (ATG7)

5. **ATG13 and ATG101**
   - Components of the ULK1 kinase complex
   - PDB examples: 5XV3, 5XV4, 5XV6 (ATG101-ATG13 complexes), 3WAN (ATG13 LIR)
   - UniProt: O75143 (ATG13)

6. **ATG9A and ATG9B**
   - Transmembrane proteins for membrane trafficking
   - PDB examples: 8POE (ATG9B)
   - UniProt: Q7Z3C6 (ATG9A), Q674R7 (ATG9B)

### **Regulatory Proteins:**

7. **ULK1/2** - Serine/threonine kinases initiating autophagy
   - PDB: 9C82 (ULK1-PI3KC3 supercomplex), 6HYO (ULK1 LIR)

8. **Beclin 1** - Key component of PI3K complex III
   - PDB: 6HOJ, 6HOK (Beclin1 LIR complexes), 3DVU (Beclin1 BH3 domain)

9. **VPS34** - Phosphatidylinositol 3-kinase
   - PDB: 6HOG, 6HOH (VPS34 LIR complexes), 8SOR (PI3KC3-C1 complex)

10. **ATG14** - Autophagy-specific component of PI3K complex
    - PDB: 6HOL (ATG14 LIR)

### **Autophagy Receptors:**

11. **NDP52** - Selective autophagy receptor
    - PDB: 4XKL (NDP52 ZF2-ubiquitin complex), 2MXP (NDP52 zinc finger)

All these proteins are directly involved in the autophagy pathway (GO:0006914), which is the cellular catabolic process for digesting cellular materials, organelles, and providing nutrients under stress conditions.

The human autophagy machinery is well-characterized structurally, with over 2,900 PDB entries related to autophagy proteins, providing detailed molecular insights into autophagosome formation, cargo recognition, and membrane dynamics.",,91.61181282997131,55,3736,28517,376251,"mcp__pubdictionaries__search, mcp__ols__search, mcp__togomcp__search_reactome_entity, mcp__togomcp__get_MIE_file, mcp__togomcp__run_sparql, mcp__togomcp__search_uniprot_entity, mcp__pubmed__search_articles, mcp__togomcp__search_uniprot_entity, mcp__togomcp__run_sparql, mcp__togomcp__search_pdb_entity, mcp__togomcp__search_pdb_entity, mcp__togomcp__run_sparql, mcp__togomcp__search_pdb_entity, mcp__togomcp__search_pdb_entity, mcp__togomcp__search_pdb_entity, mcp__togomcp__search_pdb_entity, mcp__togomcp__convertId, mcp__ols__fetch","[{""name"": ""mcp__pubdictionaries__search"", ""input"": {""labels"": ""autophagy"", ""dictionary"": ""UniProt""}}, {""name"": ""mcp__ols__search"", ""input"": {""query"": ""autophagy""}}, {""name"": ""mcp__togomcp__search_reactome_entity"", ""input"": {""query"": ""autophagy"", ""types"": [""Pathway""], ""rows"": 10}}, {""name"": ""mcp__togomcp__get_MIE_file"", ""input"": {""dbname"": ""reactome""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""reactome"", ""sparql_query"": ""PREFIX rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX biopax: <http://www.biopax.org/release/biopax-level3.owl#>\n\nSELECT DISTINCT ?protein ?proteinName ?uniprotId\nWHERE {\n  ?pathway a biopax:Pathway .\n  ?pathway biopax:displayName \""Autophagy\"" .\n  ?pathway biopax:organism ?organism .\n  ?organism biopax:displayName \""Homo sapiens\"" .\n  ?pathway biopax:pathwayComponent* ?component .\n  ?component biopax:participant ?protein .\n  ?protein a biopax:Protein .\n  ?protein biopax:displayName ?proteinName .\n  ?protein biopax:entityReference ?proteinRef .\n  ?proteinRef biopax:xref ?xref .\n  ?xref biopax:db \""UniProt\"" .\n  ?xref biopax:id ?uniprotId .\n}\nLIMIT 100""}}, {""name"": ""mcp__togomcp__search_uniprot_entity"", ""input"": {""query"": ""autophagy ATG"", ""limit"": 20}}, {""name"": ""mcp__pubmed__search_articles"", ""input"": {""query"": ""autophagy proteins structure PDB"", ""max_results"": 10}}, {""name"": ""mcp__togomcp__search_uniprot_entity"", ""input"": {""query"": ""autophagy human ATG"", ""limit"": 30}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""uniprot"", ""sparql_query"": ""PREFIX up: <http://purl.uniprot.org/core/>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX taxon: <http://purl.uniprot.org/taxonomy/>\n\nSELECT DISTINCT ?protein ?name ?pdbId\nWHERE {\n  ?protein a up:Protein ;\n           up:organism taxon:9606 ;\n           up:recommendedName ?recommendedName ;\n           rdfs:seeAlso ?pdbRef .\n  ?recommendedName up:fullName ?name .\n  ?pdbRef up:database <http://purl.uniprot.org/database/PDB> ;\n          rdfs:label ?pdbId .\n  FILTER(CONTAINS(LCASE(?name), \""autophagy\"") || CONTAINS(LCASE(?name), \""atg\""))\n}\nLIMIT 50""}}, {""name"": ""mcp__togomcp__search_pdb_entity"", ""input"": {""db"": ""pdb"", ""query"": ""autophagy"", ""limit"": 30}}, {""name"": ""mcp__togomcp__search_pdb_entity"", ""input"": {""db"": ""pdb"", ""query"": ""ATG protein"", ""limit"": 30}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""pdb"", ""sparql_query"": ""PREFIX rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX PDBo: <http://rdf.wwpdb.org/schema/pdbx-v50.owl#>\nPREFIX dc: <http://purl.org/dc/elements/1.1/>\n\nSELECT DISTINCT ?pdbId ?title ?uniprotId\nWHERE {\n  ?entity a PDBo:datablock ;\n          dc:title ?title ;\n          PDBo:has_entity_polyCategory ?entityCat .\n  ?entityCat PDBo:has_entity_poly ?poly .\n  ?poly PDBo:entity_poly.pdbx_gene_src_scientific_name ?organism .\n  OPTIONAL {\n    ?poly PDBo:reference_to_struct_ref ?structRef .\n    ?structRef PDBo:has_struct_refCategory ?refCat .\n    ?refCat PDBo:has_struct_ref ?ref .\n    ?ref PDBo:struct_ref.db_name \""UNP\"" ;\n         PDBo:struct_ref.db_code ?uniprotId .\n  }\n  BIND(REPLACE(STR(?entity), \""http://rdf.wwpdb.org/pdb/\"", \""\"") AS ?pdbId)\n  FILTER(REGEX(?title, \""autophagy|ATG\"", \""i\""))\n  FILTER(?organism = \""Homo sapiens\"")\n}\nLIMIT 50""}}, {""name"": ""mcp__togomcp__search_pdb_entity"", ""input"": {""db"": ""pdb"", ""query"": ""ATG8 ATG12 ATG5 ATG3 ATG7 LC3"", ""limit"": 30}}, {""name"": ""mcp__togomcp__search_pdb_entity"", ""input"": {""db"": ""pdb"", ""query"": ""LC3 GABARAP human"", ""limit"": 30}}, {""name"": ""mcp__togomcp__search_pdb_entity"", ""input"": {""db"": ""pdb"", ""query"": ""ATG4 human"", ""limit"": 20}}, {""name"": ""mcp__togomcp__search_pdb_entity"", ""input"": {""db"": ""pdb"", ""query"": ""ULK1 beclin"", ""limit"": 20}}, {""name"": ""mcp__togomcp__convertId"", ""input"": {""ids"": ""Q9H1Y0,O94817,Q9NT62,Q8WYN0,Q9Y4P1,O95352,O75143,Q2TAZ0,Q7Z3C6"", ""route"": ""uniprot,pdb"", ""limit"": ""100""}}, {""name"": ""mcp__ols__fetch"", ""input"": {""id"": ""go+http://purl.obolibrary.org/obo/GO_0006914""}}]",VALUABLE,Human proteins with autophagy GO annotations that also have PDB structural data,"COMPLEX QUERY requiring multi-database integration.

Databases/Resources: UniProt, GO, PDB

Knowledge Required:
- GO annotation via up:classifiedWith
- PDB cross-references via rdfs:seeAlso with URI filtering
- up:reviewed 1 filter essential
- Multiple criteria combination

Without proper knowledge: Cannot combine GO and PDB cross-references correctly.

Verified in uniprot_exploration.md (complex filtering patterns)."
88,2026-01-31,Integration,What external database links are available for ChEMBL compound CHEMBL1380?,True,False,True,0.6666666666666666,"I don't have specific information about the external database links for ChEMBL compound CHEMBL1380 in my training data. 

However, I can tell you that ChEMBL compounds typically have cross-references to various external databases such as:

- PubChem
- DrugBank
- UniChem (which aggregates links to many other databases)
- PDB (Protein Data Bank)
- Wikipedia
- Guide to Pharmacology
- Drug names and synonyms databases

To find the specific external database links for CHEMBL1380, you would need to:
1. Visit the ChEMBL website (www.ebi.ac.uk/chembl)
2. Search for CHEMBL1380
3. Look at the compound report page which lists all cross-references

I cannot provide the specific links for this compound without accessing the ChEMBL database directly.",,5.359618186950684,56,203,True,True,0.6666666666666666,"Excellent! Now I have comprehensive information about CHEMBL1380 (Abacavir) and its external database links.

## External Database Links for ChEMBL Compound CHEMBL1380

**CHEMBL1380** is **Abacavir**, a marketed small molecule drug (Development Phase 4) with ATC classification J05AF06 (antiretroviral agent).

### Available External Database Links:

**Chemical Databases:**
1. **PubChem Compound**: CID 441300
   - http://pubchem.ncbi.nlm.nih.gov/compound/441300
2. **PubChem Substance**: SID 14775540, 14799909
   - http://pubchem.ncbi.nlm.nih.gov/substance/14775540
   - http://pubchem.ncbi.nlm.nih.gov/substance/14799909
3. **ChEBI**: CHEBI:421707
   - http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI%3A421707
4. **ZINC**: ZINC000002015928
   - http://zinc15.docking.org/substances/ZINC000002015928

**Drug & Pharmacology Databases:**
5. **DrugBank**: DB01048
   - http://www.drugbank.ca/drugs/DB01048
6. **Guide to Pharmacology**: Ligand ID 11152
   - http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11152
7. **PharmGKB**: PA448004
   - https://www.pharmgkb.org/drug/PA448004
8. **FDA UNII**: WR2TIP26VS
   - https://precision.fda.gov/uniisearch/srs/unii/WR2TIP26VS

**Research & Commercial Databases:**
9. **LINCS Small Molecule**: LSM-43340
   - http://identifiers.org/lincs.smallmolecule/LSM-43340
10. **SureChEMBL**: SCHEMBL38632
    - https://www.surechembl.org/chemical/SCHEMBL38632
11. **eMolecules**: VID 30512521
    - https://www.emolecules.com/cgi-bin/more?vid=30512521
12. **HMDB**: HMDB0015182
    - http://www.hmdb.ca/metabolites/HMDB0015182

**Japanese & PDB Databases:**
13. **PDBeChem**: 1KX
    - http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/1KX
14. **KEGG**: C07624
    - http://www.genome.jp/dbget-bin/www_bget?C07624
15. **J-GLOBAL (Nikkaji)**: J825.172J
    - http://jglobal.jst.go.jp/en/redirect?Nikkaji_No=J825.172J

**Semantic Web:**
16. **skos:exactMatch** to ChEBI:
    - http://purl.obolibrary.org/obo/CHEBI_421707

These cross-references connect Abacavir to a comprehensive network of chemical, pharmaceutical, and biological databases, enabling integrated queries across multiple data sources.",,38.39045715332031,21,1762,13268,129555,"mcp__togomcp__get_MIE_file, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql","[{""name"": ""mcp__togomcp__get_MIE_file"", ""input"": {""dbname"": ""chembl""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""PREFIX cco: <http://rdf.ebi.ac.uk/terms/chembl#>\nPREFIX skos: <http://www.w3.org/2004/02/skos/core#>\n\nSELECT ?xref ?xrefType\nFROM <http://rdf.ebi.ac.uk/dataset/chembl>\nWHERE {\n  <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL1380> cco:moleculeXref ?xref .\n  BIND(\n    IF(STRSTARTS(STR(?xref), \""http://www.drugbank.ca/\""), \""DrugBank\"",\n    IF(STRSTARTS(STR(?xref), \""http://pubchem.ncbi.nlm.nih.gov/\""), \""PubChem\"",\n    IF(STRSTARTS(STR(?xref), \""http://purl.obolibrary.org/obo/CHEBI_\""), \""ChEBI\"",\n    IF(STRSTARTS(STR(?xref), \""http://identifiers.org/zinc/\""), \""ZINC\"",\n    IF(STRSTARTS(STR(?xref), \""http://linkedchemistry.info/chembl/chemblid/\""), \""LinkedChemistry\"",\n    \""Other\""))))) AS ?xrefType\n  )\n}\nORDER BY ?xrefType""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""PREFIX cco: <http://rdf.ebi.ac.uk/terms/chembl#>\nPREFIX skos: <http://www.w3.org/2004/02/skos/core#>\n\nSELECT ?label ?chemblId ?substanceType ?developmentPhase ?atc ?exactMatch\nFROM <http://rdf.ebi.ac.uk/dataset/chembl>\nWHERE {\n  <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL1380> \n    rdfs:label ?label ;\n    cco:chemblId ?chemblId ;\n    cco:substanceType ?substanceType .\n  OPTIONAL { <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL1380> cco:highestDevelopmentPhase ?developmentPhase }\n  OPTIONAL { <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL1380> cco:atcClassification ?atc }\n  OPTIONAL { <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL1380> skos:exactMatch ?exactMatch }\n}""}}]",CRITICAL,"DrugBank (DB01048), PubChem, and other cross-references for Abacavir","COMPLEX QUERY requiring cross-reference navigation.

Databases/Resources: ChEMBL

Knowledge Required:
- cco:moleculeXref property for cross-references
- Multiple database filters (DrugBank, PubChem, etc.)
- URI pattern recognition for different databases
- Pre-filtering for performance

Without proper knowledge: Cannot navigate cross-reference structure efficiently.

Verified in chembl_exploration.md Pattern 3 and simple queries section."
89,2026-01-31,Completeness,How many human kinases have expert curation in UniProt?,True,False,True,0.5714285714285714,"I don't have access to real-time UniProt database statistics, so I cannot provide you with the exact current number of human kinases with expert curation.

However, I can provide some context:

1. **Human kinome size**: The human kinome contains approximately 518-538 protein kinases, depending on classification criteria.

2. **UniProt expert curation**: Expert-curated entries in UniProt are found in the **UniProtKB/Swiss-Prot** section (as opposed to the computationally annotated UniProtKB/TrEMBL section).

3. **General coverage**: Human proteins, especially well-studied ones like kinases, tend to have high representation in Swiss-Prot due to their biological and clinical importance.

To get the current exact number, you would need to:
- Query UniProt directly using their website or API
- Filter for human proteins (taxonomy ID: 9606)
- Filter for reviewed entries (Swiss-Prot)
- Filter for kinase activity or the protein kinase family classification

The number would likely be several hundred human kinases with expert curation, as kinases are among the most intensively studied protein families, but I cannot give you a precise figure without accessing the database.",,9.066774129867554,51,281,True,True,0.8571428571428571,"Based on the SPARQL query of UniProt's RDF database, there are **2,006 human kinases with expert curation** in UniProt.

This count includes proteins from human (taxonomy ID: 9606) that:
1. Are expertly curated (reviewed entries in UniProt/Swiss-Prot)
2. Have ""kinase"" in their keyword annotations

The `up:reviewed true` filter specifically ensures we're only counting entries that have undergone expert manual curation by UniProt curators, as opposed to automatically annotated entries in UniProt/TrEMBL.",,24.453937768936157,9,406,26781,26493,mcp__togomcp__run_sparql,"[{""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""uniprot"", ""sparql_query"": ""\nPREFIX up: <http://purl.uniprot.org/core/>\nPREFIX taxon: <http://purl.uniprot.org/taxonomy/>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT (COUNT(DISTINCT ?protein) as ?count)\nWHERE {\n  ?protein a up:Protein ;\n           up:organism taxon:9606 ;\n           up:reviewed true ;\n           up:classifiedWith ?keyword .\n  ?keyword rdfs:label ?label .\n  FILTER(CONTAINS(LCASE(?label), \""kinase\""))\n}\n""}}]",CRITICAL,Count of reviewed human proteins with kinase-related annotations,"COMPLEX QUERY requiring text search and counting.

Databases/Resources: UniProt

Knowledge Required:
- bif:contains for 'kinase' in protein names
- Property path splitting for name search
- up:reviewed 1 filter CRITICAL
- Human organism filter
- COUNT aggregation

Without proper knowledge: Property path error with bif:contains or timeout without reviewed filter.

Verified in uniprot_exploration.md Pattern 2."
90,2026-01-31,Completeness,What is the distribution of clinical significance classifications across all ClinVar variants?,True,False,False,0.125,"Based on my training knowledge of ClinVar, the distribution of clinical significance classifications typically follows this general pattern:

## Major Categories:

1. **Benign/Likely Benign**: ~45-50% of classified variants
   - These represent the largest proportion of submissions

2. **Uncertain Significance (VUS)**: ~35-40%
   - This is a very substantial category representing variants where evidence is insufficient for classification

3. **Pathogenic/Likely Pathogenic**: ~10-15%
   - Disease-causing variants that are clinically actionable

4. **Conflicting Interpretations**: ~2-5%
   - Variants where different submitters have provided different classifications

5. **Other categories**: <1-2%
   - Includes: drug response, risk factor, protective, affects, association, etc.

## Important Notes:

- **These percentages shift over time** as more evidence accumulates and variants get reclassified
- Many variants in ClinVar have **no assertion provided** or lack expert review
- The distribution varies significantly by:
  - **Gene**: Some genes have more characterized variants than others
  - **Variant type**: SNVs vs. indels vs. structural variants
  - **Review status**: Star ratings affect confidence in classifications
  
- There's been a trend toward **reducing VUS rates** as more data becomes available, but VUS still represents a significant challenge in clinical interpretation

For the most current and precise distribution, you would need to query the latest ClinVar database directly.",,10.486481189727783,52,344,True,False,0.125,"Let me calculate the total from the data I already have:

## Distribution of Clinical Significance Classifications in ClinVar

Based on the query of current ClinVar variants with germline clinical significance classifications, here's the comprehensive distribution:

### Summary Statistics
- **Total classified variants**: 3,586,601 variants
- **Number of distinct classifications**: 91 different categories

### Major Clinical Significance Categories

| Clinical Significance | Count | Percentage |
|----------------------|---------|------------|
| **Uncertain significance** | 1,821,577 | 50.8% |
| **Likely benign** | 993,150 | 27.7% |
| **Benign** | 213,802 | 6.0% |
| **Pathogenic** | 200,004 | 5.6% |
| **Conflicting classifications of pathogenicity** | 145,497 | 4.1% |
| **Likely pathogenic** | 107,204 | 3.0% |
| **Benign/Likely benign** | 53,812 | 1.5% |
| **Pathogenic/Likely pathogenic** | 34,673 | 1.0% |
| **Not provided** | 11,652 | 0.3% |
| **Drug response** | 2,516 | 0.07% |
| **Other** | 1,606 | 0.04% |
| **Risk factor** | 442 | 0.01% |
| All other categories | <500 each | <0.01% each |

### Key Insights

1. **Uncertain significance dominates**: Over half (50.8%) of all ClinVar variants are classified as ""Uncertain significance,"" indicating that for many genetic variants, there isn't enough evidence to determine their clinical impact.

2. **Benign variants are common**: When combining benign categories (Benign + Likely benign + Benign/Likely benign), they represent **35.2%** of all variants, making them the second most common group.

3. **Pathogenic variants**: Combined pathogenic categories (Pathogenic + Likely pathogenic + Pathogenic/Likely pathogenic) account for **9.5%** of variants.

4. **Conflicting interpretations**: About 4.1% of variants have conflicting classifications, highlighting disagreements among different laboratories or submissions.

5. **Complex classifications**: There are 91 distinct classification values, including many compound classifications (e.g., ""Pathogenic; drug response"") that indicate variants with multiple clinical implications.

This distribution reflects the ongoing challenge in variant interpretation, where roughly half of reported variants still require additional evidence for clinical decision-making.",,47.94721722602844,24,1269,13865,158236,"mcp__togomcp__get_sparql_endpoints, mcp__togomcp__get_MIE_file, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql","[{""name"": ""mcp__togomcp__get_sparql_endpoints"", ""input"": {}}, {""name"": ""mcp__togomcp__get_MIE_file"", ""input"": {""dbname"": ""clinvar""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""clinvar"", ""sparql_query"": ""PREFIX cvo: <http://purl.jp/bio/10/clinvar/>\n\nSELECT ?significance (COUNT(?variant) as ?count)\nFROM <http://rdfportal.org/dataset/clinvar>\nWHERE {\n  ?variant a cvo:VariationArchiveType ;\n           cvo:record_status \""current\"" ;\n           cvo:classified_record ?classrec .\n  ?classrec cvo:classifications/cvo:germline_classification/cvo:description ?significance .\n}\nGROUP BY ?significance\nORDER BY DESC(?count)""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""clinvar"", ""sparql_query"": ""PREFIX cvo: <http://purl.jp/bio/10/clinvar/>\n\nSELECT (COUNT(DISTINCT ?variant) as ?total_variants)\nFROM <http://rdfportal.org/dataset/clinvar>\nWHERE {\n  ?variant a cvo:VariationArchiveType ;\n           cvo:record_status \""current\"" ;\n           cvo:classified_record ?classrec .\n  ?classrec cvo:classifications/cvo:germline_classification/cvo:description ?significance .\n}""}}]",CRITICAL,"Uncertain significance: 51% (1,821,577), Likely benign: 28% (993,150), Benign: 6% (213,802), Pathogenic: 6% (200,004), Conflicting: 4% (145,497)","COMPLEX QUERY requiring classification aggregation.

Databases/Resources: ClinVar

Knowledge Required:
- Property path for significance classification
- GROUP BY for aggregation
- record_status 'current' filter
- COUNT for distribution

Without proper knowledge: Cannot navigate nested classification structure.

Verified in clinvar_exploration.md Pattern 5."
91,2026-01-31,Specificity,Which GO biological processes have Reactome pathway cross-references?,True,False,False,0.42857142857142855,"I don't have access to a specific database or current cross-reference mappings between GO (Gene Ontology) biological processes and Reactome pathways in my training data that would allow me to give you a comprehensive, accurate list.

However, I can tell you that:

1. **Many GO biological processes have Reactome cross-references**, as both databases aim to describe biological processes and frequently cross-reference each other.

2. **Common areas with cross-references** typically include:
   - Metabolic processes (amino acid metabolism, carbohydrate metabolism, lipid metabolism, etc.)
   - Signal transduction pathways
   - Cell cycle processes
   - DNA repair and replication
   - Immune system processes
   - Apoptosis and programmed cell death
   - Protein processing and degradation

3. **To find the current cross-references**, you would need to:
   - Query the GO database directly (using tools like AmiGO or QuickGO)
   - Check the Reactome database
   - Use the GO annotation files which include database cross-references
   - Look at the GO term entries which list ""Dbxrefs"" (database cross-references)

If you need specific, up-to-date information about which exact GO terms have Reactome cross-references, I'd recommend querying the GO or Reactome databases directly, as these mappings are regularly updated.",,8.302578926086426,50,314,True,True,0.8571428571428571,"Excellent! I now have comprehensive information about GO biological processes with Reactome pathway cross-references. Let me provide you with a detailed answer.

## GO Biological Processes with Reactome Pathway Cross-References

I found **795 distinct GO biological processes** that have cross-references to Reactome pathways. These cross-references link Gene Ontology biological process terms to specific Reactome pathway identifiers (in the format ""Reactome:R-HSA-XXXXX"").

### Categories of Cross-Referenced Processes

The GO biological processes with Reactome cross-references span a wide range of cellular functions, including:

#### **1. Cell Cycle & Division**
- Mitotic cell cycle (GO:0000278) → Reactome:R-HSA-69278
- G1/S transition of mitotic cell cycle (GO:0000082) → Reactome:R-HSA-69206
- G2/M transition of mitotic cell cycle (GO:0000086) → Reactome:R-HSA-69275
- Mitotic M phase (GO:0000087) → Reactome:R-HSA-68886

#### **2. Signal Transduction**
- MAPK cascade (GO:0000165) → Reactome:R-HSA-169893, R-HSA-5673001
- G protein-coupled receptor signaling pathway (GO:0007186) → Reactome:R-HSA-373076, R-HSA-388396
- Wnt signaling pathway (GO:0016055) → Reactome:R-HSA-195721
- Notch signaling pathway (GO:0007219) → Reactome:R-HSA-157118
- BMP signaling pathway (GO:0030509) → Reactome:R-HSA-201451
- T cell receptor signaling pathway (GO:0050852) → Reactome:R-HSA-202403

#### **3. Immune System**
- Adaptive immune response (GO:0002250) → Reactome:R-HSA-1280218
- Toll-like receptor signaling pathway (GO:0002224) → Reactome:R-HSA-168898
- MyD88-dependent toll-like receptor signaling (GO:0002755) → Reactome:R-HSA-166058, R-HSA-975871
- Fc-epsilon receptor signaling pathway (GO:0038095) → Reactome:R-HSA-2454202

#### **4. DNA Metabolism**
- DNA replication (GO:0006260) → Reactome:R-HSA-176187, R-HSA-69239
- DNA repair (GO:0006281) → Reactome:R-HSA-73894
- DNA alkylation repair (GO:0006307) → Reactome:R-HSA-5657655, R-HSA-73943
- DNA-templated transcription (GO:0006351) → Reactome:R-HSA-2173793, R-HSA-74160

#### **5. Metabolic Processes**
- Carbohydrate metabolic process (GO:0005975) → Reactome:R-HSA-71387
- Tricarboxylic acid cycle (GO:0006099) → Reactome:R-HSA-71403
- Glycolysis (GO:0006096) → Reactome:R-HSA-70171
- Pentose-phosphate shunt (GO:0006098) → Reactome:R-HSA-71336
- Urea cycle (GO:0000050) → Reactome:R-HSA-70635

#### **6. RNA Processing**
- mRNA splicing, via spliceosome (GO:0000398) → Reactome:R-HSA-72163, R-HSA-72165
- rRNA modification (GO:0000154) → Reactome:R-HSA-6790901, R-HSA-6793080
- Nonsense-mediated decay (GO:0000184) → Reactome:R-HSA-927802

### Key Insights

1. **Many-to-many relationships**: Some GO terms map to multiple Reactome pathways, and vice versa, reflecting the complexity of biological processes.

2. **Comprehensive coverage**: The cross-references cover fundamental cellular processes including metabolism, signaling, gene expression, cell cycle, and immune responses.

3. **Integration value**: These cross-references enable researchers to:
   - Navigate between Gene Ontology annotations and detailed pathway information in Reactome
   - Connect gene function (GO) with mechanistic pathway knowledge (Reactome)
   - Perform integrated pathway enrichment analyses

The cross-references are stored in the GO RDF data using the `oboinowl:hasDbXref` property with identifiers in the format ""Reactome:R-HSA-XXXXX"".",,59.02707314491272,26,2535,35326,219993,"mcp__togomcp__get_MIE_file, mcp__togomcp__get_MIE_file, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql","[{""name"": ""mcp__togomcp__get_MIE_file"", ""input"": {""dbname"": ""go""}}, {""name"": ""mcp__togomcp__get_MIE_file"", ""input"": {""dbname"": ""reactome""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""go"", ""sparql_query"": ""PREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX oboinowl: <http://www.geneontology.org/formats/oboInOwl#>\nPREFIX obo: <http://purl.obolibrary.org/obo/>\nPREFIX xsd: <http://www.w3.org/2001/XMLSchema#>\n\nSELECT DISTINCT ?go ?goLabel ?reactomeXref\nFROM <http://rdfportal.org/ontology/go>\nWHERE {\n  ?go a <http://www.w3.org/2002/07/owl#Class> ;\n      rdfs:label ?goLabel ;\n      oboinowl:hasOBONamespace \""biological_process\""^^xsd:string ;\n      oboinowl:hasDbXref ?reactomeXref .\n  FILTER(STRSTARTS(STR(?go), \""http://purl.obolibrary.org/obo/GO_\""))\n  FILTER(REGEX(?reactomeXref, \""^Reactome:\"", \""i\""))\n}\nORDER BY ?go\nLIMIT 100""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""go"", ""sparql_query"": ""PREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX oboinowl: <http://www.geneontology.org/formats/oboInOwl#>\nPREFIX obo: <http://purl.obolibrary.org/obo/>\nPREFIX xsd: <http://www.w3.org/2001/XMLSchema#>\n\nSELECT (COUNT(DISTINCT ?go) as ?count)\nFROM <http://rdfportal.org/ontology/go>\nWHERE {\n  ?go a <http://www.w3.org/2002/07/owl#Class> ;\n      oboinowl:hasOBONamespace \""biological_process\""^^xsd:string ;\n      oboinowl:hasDbXref ?reactomeXref .\n  FILTER(STRSTARTS(STR(?go), \""http://purl.obolibrary.org/obo/GO_\""))\n  FILTER(REGEX(?reactomeXref, \""^Reactome:\"", \""i\""))\n}""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""go"", ""sparql_query"": ""PREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX oboinowl: <http://www.geneontology.org/formats/oboInOwl#>\nPREFIX obo: <http://purl.obolibrary.org/obo/>\nPREFIX xsd: <http://www.w3.org/2001/XMLSchema#>\n\nSELECT DISTINCT ?goId ?goLabel ?definition (GROUP_CONCAT(DISTINCT ?reactomeXref; separator=\""; \"") as ?reactomeRefs)\nFROM <http://rdfportal.org/ontology/go>\nWHERE {\n  ?go a <http://www.w3.org/2002/07/owl#Class> ;\n      oboinowl:id ?goId ;\n      rdfs:label ?goLabel ;\n      oboinowl:hasOBONamespace \""biological_process\""^^xsd:string ;\n      oboinowl:hasDbXref ?reactomeXref .\n  OPTIONAL { ?go obo:IAO_0000115 ?definition }\n  FILTER(STRSTARTS(STR(?go), \""http://purl.obolibrary.org/obo/GO_\""))\n  FILTER(REGEX(?reactomeXref, \""^Reactome:\"", \""i\""))\n  FILTER(CONTAINS(?goLabel, \""signaling\"") || CONTAINS(?goLabel, \""immune\"") || CONTAINS(?goLabel, \""cell cycle\"") || CONTAINS(?goLabel, \""metabolism\"") || CONTAINS(?goLabel, \""DNA\""))\n}\nGROUP BY ?goId ?goLabel ?definition\nORDER BY ?goLabel\nLIMIT 30""}}]",CRITICAL,GO biological processes with Reactome: prefix in hasDbXref property,"COMPLEX QUERY requiring cross-reference knowledge.

Databases/Resources: GO

Knowledge Required:
- hasDbXref property for cross-references
- STRSTARTS filter for 'Reactome:' prefix
- Namespace filtering for biological_process
- FROM clause for consistent results

Without proper knowledge: Cannot identify Reactome cross-references.

Verified in go_exploration.md Pattern 7."
92,2026-01-31,Specificity,What are all the ancestor biological processes of 'mitophagy' in Gene Ontology?,True,True,True,0.6923076923076923,"I need to clarify that I should provide information based on my training knowledge, which has a cutoff date, so the Gene Ontology (GO) structure I describe may have been updated since then.

Based on my knowledge, **mitophagy** (GO:0000422) is the selective degradation of mitochondria by autophagy. Here are its ancestor biological processes in the Gene Ontology hierarchy:

**Direct lineage path:**

1. **mitophagy** (GO:0000422)
   ↓
2. **autophagy of mitochondrion** (GO:0000422 or related term)
   ↓
3. **macroautophagy** (GO:0016236) - the major form of autophagy
   ↓
4. **autophagy** (GO:0006914) - general autophagy process
   ↓
5. **catabolic process** (GO:0009056) - breakdown of substances
   ↓
6. **metabolic process** (GO:0008152) - chemical transformations
   ↓
7. **biological_process** (GO:0008150) - the root term

Mitophagy may also have relationships to:
- **organelle organization** and related terms
- **mitochondrion organization** (GO:0007005)
- **cellular process** (GO:0009987)

The exact path can vary slightly depending on how the ontology curators have structured the relationships, and there may be multiple valid paths through the directed acyclic graph structure of GO.

For the most current and accurate ancestry information, I recommend checking the official Gene Ontology database or browsers like QuickGO or AmiGO.",,9.478258848190308,58,396,True,True,0.9230769230769231,"Perfect! Here are all the ancestor biological processes of **mitophagy (GO:0000423)** in Gene Ontology:

## Ancestor Biological Processes of Mitophagy

The hierarchical ancestry of mitophagy includes the following biological processes (ordered from immediate parent to root):

1. **GO:0000422 - autophagy of mitochondrion**
   - The autophagic process in which mitochondria are delivered to a type of vacuole and degraded in response to changing cellular conditions.

2. **GO:0016236 - macroautophagy**
   - The autophagic process that proceeds via the formation of an autophagosome.

3. **GO:0006914 - autophagy**
   - The cellular catabolic process in which cells digest cellular materials, such as organelles and other macromolecular constituents, or non-self materials such as intracellular pathogens.

4. **GO:0061919 - process utilizing autophagic mechanism**
   - A cellular process involving delivery of a portion of the cytoplasm to lysosomes or vacuoles that does not involve direct transport through the endocytic or vacuolar protein sorting pathways.

5. **GO:0009056 - catabolic process**
   - A cellular process consisting of the biochemical pathways by which a living organism breaks down substances, including the breakdown of carbon compounds with the liberation of energy.

6. **GO:0008152 - metabolic process**
   - A cellular process consisting of the biochemical pathways by which a living organism transforms chemical substances.

7. **GO:0009987 - cellular process**
   - Any process that is carried out at the cellular level, but not necessarily restricted to a single cell.

8. **GO:0008150 - biological_process**
   - The root term of the biological process ontology representing the execution of a genetically-encoded biological module or program.

The ancestry also includes upper-level ontology terms from BFO (Basic Formal Ontology):
- **BFO:0000015 - process**
- **BFO:0000003 - occurrent**

This hierarchy shows that mitophagy is a specialized form of autophagy focused on mitochondrial degradation, which falls under the broader categories of catabolic and metabolic processes.",,23.361147165298462,14,785,6171,80655,"mcp__ols__search, mcp__ols__getAncestors","[{""name"": ""mcp__ols__search"", ""input"": {""query"": ""mitophagy""}}, {""name"": ""mcp__ols__getAncestors"", ""input"": {""ontologyId"": ""go"", ""classIri"": ""http://purl.obolibrary.org/obo/GO_0000423""}}]",VALUABLE,"Ancestor terms including autophagy (GO:0006914), catabolic process, cellular process, and process utilizing autophagic mechanism","COMPLEX QUERY requiring full hierarchy traversal.

Databases/Resources: GO

Knowledge Required:
- rdfs:subClassOf traversal for ancestor path
- FROM clause for consistent results
- STRSTARTS filter for GO URIs
- Transitive closure for complete ancestors

Without proper knowledge: Missing FROM clause or incorrect traversal pattern.

Verified in go_exploration.md Pattern 6."
93,2026-01-31,Currency,What experimental methods have been used to determine BRCA1 protein structures?,True,True,True,1.0,"Based on my training knowledge, several experimental methods have been used to determine BRCA1 protein structures:

## X-ray Crystallography
This has been the primary method for determining BRCA1 domain structures:
- **RING domain** - Structures of the BRCA1 RING domain in complex with BARD1 RING domain have been solved, revealing their heterodimeric E3 ubiquitin ligase structure
- **BRCT domains** - The tandem BRCT repeats at the C-terminus have been crystallized, both alone and in complex with phosphopeptides, revealing how they recognize phosphorylated binding partners

## Nuclear Magnetic Resonance (NMR) Spectroscopy
NMR has been used to study:
- Individual BRCA1 domains in solution
- Domain dynamics and interactions with peptides
- Some structural characterization of smaller BRCA1 fragments

## Challenges and Limitations
It's important to note that:
- **No full-length structure exists** - BRCA1 is a large (1863 amino acids), multi-domain protein that has been difficult to express and purify in full-length form
- **Only individual domains solved** - Structural information is limited to isolated domains (RING, BRCT) or domain complexes
- The central region of BRCA1 remains largely unstructured or poorly characterized structurally

## More Recent Approaches
Cryo-electron microscopy (cryo-EM) may have been applied to larger BRCA1-containing complexes, though my knowledge of specific applications is limited.

The lack of a complete BRCA1 structure reflects technical challenges common to large, multi-domain proteins with intrinsically disordered regions.",,10.625468015670776,53,397,True,True,1.0,"Perfect! Now I have comprehensive information about the experimental methods used to determine BRCA1 protein structures. Let me provide you with a detailed summary.

## Experimental Methods Used to Determine BRCA1 Protein Structures

Based on the Protein Data Bank (PDB) database, **three main experimental methods** have been used to determine BRCA1 protein structures:

### 1. **X-ray Crystallography (X-RAY DIFFRACTION)** - Most Common Method
This is by far the most widely used method, accounting for the majority of BRCA1 structures. Key structures include:

- **BRCT Domain Studies**: The tandem BRCT (BRCA1 C-Terminal) repeats have been extensively studied, including:
  - First structure of BRCT repeats (1JNX, 2001)
  - BRCT domains bound to phosphorylated peptides from binding partners (BACH1, CtIP, Abraxas, ACC1, ATRIP, BAAT)
  - Disease-causing mutations and variants
  - Minimal recognition motifs

- **Examples**: 1JNX, 1T15, 1Y98, 4JLU, 4Y18, and many others (~30+ structures)

### 2. **Solution NMR Spectroscopy (SOLUTION NMR)**
Used for smaller domains and flexible regions:

- **RING Domain**: Structure of BRCA1/BARD1 RING-domain heterodimer (1JM7)
- **BRCT Domains**: Individual BRCT-c domain (1OQA)
- **Coiled-coil Region**: BRCA1-PALB2 heterodimer (7K3S, 2021)

These NMR structures provide insights into solution-state dynamics and flexibility.

### 3. **Cryo-Electron Microscopy (ELECTRON MICROSCOPY)** - Recent Advances
The newest method, primarily used since 2020 for large complexes:

- **BRCA1-BARD1 on nucleosomes** (7JZV, 7LYB, 8GRQ, 2020-2022): Shows how BRCA1 functions in chromatin context
- **BRCA1 recruitment to damaged chromatin** (7E8I)
- **ACC-BRCT filaments** (6G2H, 6G2I): Large filamentous assemblies

Cryo-EM has been crucial for understanding BRCA1 in its functional context with nucleosomes and other large complexes.

### Summary
The progression of methods reflects technological advances: X-ray crystallography dominated early structural studies (2001-2020s), NMR provided complementary solution-state information, and cryo-EM has recently enabled visualization of BRCA1 in complex with nucleosomes and chromatin—critical for understanding its DNA repair functions.",,37.720149993896484,16,1269,4403,80891,"mcp__togomcp__search_uniprot_entity, mcp__togomcp__search_pdb_entity, mcp__togomcp__run_sparql","[{""name"": ""mcp__togomcp__search_uniprot_entity"", ""input"": {""query"": ""BRCA1 human"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_pdb_entity"", ""input"": {""db"": ""pdb"", ""query"": ""BRCA1"", ""limit"": 30}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""pdb"", ""sparql_query"": ""PREFIX rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX PDBo: <http://rdf.wwpdb.org/schema/pdbx-v50.owl#>\nPREFIX dc: <http://purl.org/dc/elements/1.1/>\n\nSELECT DISTINCT ?pdbid ?method ?title\nWHERE {\n  ?entry a PDBo:datablock ;\n         dc:title ?title ;\n         PDBo:has_exptlCategory ?exptl .\n  ?exptl PDBo:has_exptl ?exptl_details .\n  ?exptl_details PDBo:exptl.method ?method .\n  \n  BIND(STRAFTER(STR(?entry), \""http://rdf.wwpdb.org/pdb/\"") AS ?pdbid)\n  \n  FILTER(CONTAINS(LCASE(?title), \""brca1\""))\n}\nORDER BY ?pdbid\nLIMIT 50""}}]",VALUABLE,"X-ray crystallography, NMR spectroscopy, and cryo-electron microscopy have been used for BRCA1 structures","COMPLEX QUERY requiring cross-reference and method knowledge.

Databases/Resources: PDB

Knowledge Required:
- UniProt cross-reference for P38398 filtering
- exptl.method property for experimental technique
- GROUP BY for method distribution
- struct_ref category for UniProt links

Without proper knowledge: Cannot combine UniProt filtering with method extraction.

Verified in pdb_exploration.md Pattern 2."
94,2026-01-31,Currency,What drugs have been developed for Type 2 diabetes with their development stages?,True,True,True,0.6153846153846154,"# Drugs Developed for Type 2 Diabetes

Type 2 diabetes has numerous drug classes at various development stages. Here's an overview:

## **Approved/Marketed Drugs**

### 1. **Biguanides**
- **Metformin** - First-line therapy, most widely used

### 2. **Sulfonylureas**
- Glipizide, Glyburide, Glimepiride - Older generation drugs

### 3. **GLP-1 Receptor Agonists**
- **Semaglutide** (Ozempic, Wegovy)
- **Dulaglutide** (Trulicity)
- **Liraglutide** (Victoza)
- **Exenatide** (Byetta)

### 4. **SGLT2 Inhibitors**
- **Empagliflozin** (Jardiance)
- **Dapagliflozin** (Farxiga)
- **Canagliflozin** (Invokana)

### 5. **DPP-4 Inhibitors**
- Sitagliptin (Januvia), Linagliptin, Saxagliptin

### 6. **Thiazolidinediones (TZDs)**
- Pioglitazone, Rosiglitazone

### 7. **Insulins**
- Various formulations (rapid, long-acting, mixed)

## **Drugs in Clinical Development**

### **Phase 3**
- Oral GLP-1 agonists (various)
- Dual and triple agonists (GLP-1/GIP, GLP-1/GIP/Glucagon)
- **Tirzepatide** - Now approved (Mounjaro)

### **Phase 2**
- Novel incretin combinations
- Glucokinase activators
- AMPK activators

### **Phase 1**
- Gene therapies
- Novel metabolic targets

**Note:** The development pipeline constantly evolves, with drugs moving between phases or being discontinued.",,9.57434606552124,53,507,True,True,0.7692307692307693,"Based on the information from the biological databases, I can provide you with comprehensive information about drugs developed for Type 2 diabetes and their development stages:

## Major Drug Classes for Type 2 Diabetes with Development Stages

### **1. GLP-1 Receptor Agonists (Glucagon-Like Peptide-1)**

**Approved (Phase 4 - Post-Market):**
- **Semaglutide** - Recently demonstrated kidney-protective effects in the FLOW trial. The REMODEL trial is exploring its mechanisms of action using advanced imaging and kidney biopsies ([DOI](https://doi.org/10.1016/j.kint.2025.10.005))

**Phase 1:**
- **LY3537021** (GIPR agonist) - A long-acting glucose-dependent insulinotropic polypeptide receptor agonist that showed weight loss and improved glucose control in Phase 1 trials. Demonstrated dose-dependent weight loss (3.14 kg with 25 mg dose) and was well tolerated with infrequent gastrointestinal side effects ([DOI](https://doi.org/10.1016/j.molmet.2025.102298))

### **2. DPP-4 Inhibitors (Dipeptidyl Peptidase-4 Inhibitors)**

**Phase 2:**
- **Cofrogliptin** - A bi-weekly DPP-4 inhibitor that showed superiority over daily DPP-4 inhibitors in Phase 2 trials in Chinese patients, with improved time in range (9.929% difference, p=0.0046) and good tolerability ([DOI](https://doi.org/10.1111/dom.70305))

**Approved:**
- **Sitagliptin** - Widely used DPP-4 inhibitor
- **Alogliptin, Saxagliptin, Anagliptin, Trelaglitazar** - Other approved DPP-4 inhibitors

### **3. SGLT2 Inhibitors (Sodium-Glucose Cotransporter-2 Inhibitors)**

**Approved:**
- **Empagliflozin** - Demonstrated nephroprotective effects and cardiovascular benefits

### **4. Mineralocorticoid Receptor Antagonists**

**Phase 3:**
- **Finerenone** - A nonsteroidal mineralocorticoid receptor antagonist showing significant benefits in Asian patients with Type 2 diabetes and chronic kidney disease. Reduced chronic eGFR decline (1.08 mL/min/1.73 m² difference, p=0.0002) and reduced UACR by 34% from baseline ([DOI](https://doi.org/10.1016/j.jdiacomp.2025.109213))

### **5. Dual GIP/GLP-1 Receptor Agonists**

**Approved:**
- **Tirzepatide** - A dual agonist showing superiority in blood glucose reduction and weight loss compared to selective GLP-1R agonists

### **6. Traditional Oral Antidiabetics**

**Approved:**
- **Metformin** - First-line therapy
- **Sulfonylureas**: Glimepiride, Chlorpropamide, Tolazamide
- **Meglitinides**: Nateglinide, Mitiglinide
- **Thiazolidinediones** (PPAR-gamma agonists): Tesaglitazar, Aleglitazar

### **7. Insulin Therapies**

**Approved:**
- Various insulin formulations: Insulin glargine, insulin detemir, insulin degludec, insulin lispro, insulin aspart, insulin glulisine, insulin icodec

### **8. Novel Therapies for Diabetic Neuropathy**

**Phase 2a:**
- **Topical Pirenzepine (4%)** - An antimuscarinic agent that showed promising results in treating diabetic peripheral neuropathy. Increased intraepidermal nerve fiber density at the ankle (2.32 difference, p=0.006 for 4 mL dose) and promoted nerve regeneration after 24 weeks of treatment ([DOI](https://doi.org/10.1016/j.ebiom.2025.106055))

## Key Trends in Drug Development:

1. **Multi-target approaches**: Drugs like tirzepatide targeting multiple pathways (GIP/GLP-1)
2. **Long-acting formulations**: Moving from daily to weekly dosing (cofrogliptin, semaglutide)
3. **Nephroprotection**: Focus on protecting kidney function (finerenone, semaglutide)
4. **Complication management**: Novel therapies for diabetic complications like neuropathy (pirenzepine)
5. **Personalized medicine**: Subpopulation studies (Asian populations, different baseline kidney functions)

---

**Sources:**
According to PubMed and ChEMBL databases:
- [DOI: 10.1111/dom.70305](https://doi.org/10.1111/dom.70305)
- [DOI: 10.1016/j.molmet.2025.102298](https://doi.org/10.1016/j.molmet.2025.102298)
- [DOI: 10.1016/j.ebiom.2025.106055](https://doi.org/10.1016/j.ebiom.2025.106055)
- [DOI: 10.1016/j.jdiacomp.2025.109213](https://doi.org/10.1016/j.jdiacomp.2025.109213)
- [DOI: 10.1016/j.kint.2025.10.005](https://doi.org/10.1016/j.kint.2025.10.005)",,109.16585803031921,43,2881,17013,248138,"mcp__pubdictionaries__search, mcp__ols__search, mcp__togomcp__search_chembl_target, mcp__togomcp__search_chembl_molecule, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__pubmed__search_articles, mcp__pubmed__get_article_metadata, mcp__pubmed__search_articles, mcp__togomcp__search_chembl_molecule","[{""name"": ""mcp__pubdictionaries__search"", ""input"": {""labels"": ""Type 2 diabetes, diabetes mellitus type 2"", ""dictionary"": ""MONDO""}}, {""name"": ""mcp__ols__search"", ""input"": {""query"": ""Type 2 diabetes mellitus""}}, {""name"": ""mcp__togomcp__search_chembl_target"", ""input"": {""query"": ""diabetes mellitus type 2"", ""limit"": 30}}, {""name"": ""mcp__togomcp__search_chembl_molecule"", ""input"": {""query"": ""diabetes type 2"", ""limit"": 30}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""PREFIX rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX cco: <http://rdf.ebi.ac.uk/terms/chembl#>\n\nSELECT DISTINCT ?molecule ?molName ?maxPhase ?indication\nWHERE {\n  ?molecule a cco:Molecule ;\n            cco:highestDevelopmentPhase ?maxPhase .\n  OPTIONAL { ?molecule rdfs:label ?molName }\n  \n  ?activity cco:hasMolecule ?molecule ;\n            cco:hasAssay ?assay .\n  \n  ?assay cco:hasTarget ?target ;\n         cco:hasDocument ?doc .\n  \n  ?indication cco:hasDocument ?doc .\n  ?indication rdfs:label ?indicationLabel .\n  \n  FILTER(REGEX(?indicationLabel, \""diabetes\"", \""i\"") || REGEX(?indicationLabel, \""diabetic\"", \""i\""))\n  FILTER(?maxPhase >= 1)\n}\nLIMIT 50""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""PREFIX cco: <http://rdf.ebi.ac.uk/terms/chembl#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT DISTINCT ?molName ?maxPhase\nWHERE {\n  ?mol a cco:Molecule ;\n       rdfs:label ?molName ;\n       cco:highestDevelopmentPhase ?maxPhase .\n  \n  ?drugInd cco:hasMolecule ?mol ;\n           cco:hasDiseaseEfoId ?disease .\n  \n  ?disease rdfs:label ?diseaseLabel .\n  \n  FILTER(REGEX(?diseaseLabel, \""type 2 diabetes\"", \""i\"") || REGEX(?diseaseLabel, \""type II diabetes\"", \""i\""))\n  FILTER(?maxPhase >= 1)\n}\nORDER BY DESC(?maxPhase)\nLIMIT 100""}}, {""name"": ""mcp__pubmed__search_articles"", ""input"": {""query"": ""type 2 diabetes drug development clinical trial phase"", ""max_results"": 20, ""sort"": ""pub_date""}}, {""name"": ""mcp__pubmed__get_article_metadata"", ""input"": {""pmids"": [""41267147"", ""41391569"", ""41352124"", ""41289823"", ""41207620""]}}, {""name"": ""mcp__pubmed__search_articles"", ""input"": {""query"": ""type 2 diabetes medications FDA approved 2024 2025"", ""max_results"": 10, ""sort"": ""pub_date""}}, {""name"": ""mcp__togomcp__search_chembl_molecule"", ""input"": {""query"": ""metformin sitagliptin empagliflozin semaglutide insulin"", ""limit"": 20}}]",VALUABLE,"Type 2 diabetes drugs with development phases: METFORMIN (phase 4), GLIPIZIDE (phase 4), SITAGLIPTIN (phase 4), etc.","COMPLEX QUERY requiring indication and phase knowledge.

Databases/Resources: ChEMBL

Knowledge Required:
- DrugIndication entity model
- hasMeshHeading for disease filtering
- highestDevelopmentPhase for status
- CONTAINS for indication keyword

Without proper knowledge: Cannot navigate DrugIndication model.

Verified in chembl_exploration.md Pattern 4."
95,2026-01-31,Precision,What is the chromosomal location of the BRCA1 gene?,True,True,True,1.0,"The BRCA1 gene is located on **chromosome 17**, specifically at the chromosomal location **17q21.31**.

This means it's on the long arm (q) of chromosome 17, at region 2, band 1, sub-band 31. BRCA1 is a tumor suppressor gene, and mutations in this gene are associated with increased risk of breast and ovarian cancers, among others.",,3.754117012023926,53,97,True,True,1.0,"The **BRCA1 gene** is located on **chromosome 17** at position **17q21.31**.

More specifically:
- **Chromosome**: 17
- **Cytogenetic location**: 17q21.31 (on the long arm ""q"" of chromosome 17, at region 21, band 31)
- **Genomic coordinates**: The gene spans from position 43,044,294 to 43,170,326 on chromosome 17 (GRCh38/hg38 assembly)
- **Size**: The gene spans approximately 110 kb (about 126 kb based on the coordinates) and contains 22 exons

BRCA1 encodes a tumor suppressor protein involved in DNA repair and maintaining genomic stability. Mutations in this gene are responsible for approximately 40% of inherited breast cancers and more than 80% of inherited breast and ovarian cancers.",,24.6611909866333,15,514,29514,53724,"mcp__togomcp__search_uniprot_entity, mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esummary","[{""name"": ""mcp__togomcp__search_uniprot_entity"", ""input"": {""query"": ""BRCA1 human"", ""limit"": 5}}, {""name"": ""mcp__togomcp__ncbi_esearch"", ""input"": {""database"": ""gene"", ""query"": ""BRCA1[Gene Name] AND Homo sapiens[Organism]"", ""max_results"": 1}}, {""name"": ""mcp__togomcp__ncbi_esummary"", ""input"": {""database"": ""gene"", ""ids"": [""672""]}}]",VALUABLE,17q21.31,"SIMPLE QUERY - Straightforward gene property lookup.

Method: ClinVar gene entity lookup for cytogenetic_location

Demonstrates when basic gene property lookups suffice.

Verified in clinvar_exploration.md Pattern 8."
96,2026-01-31,Precision,What is the equation for Rhea reaction RHEA:10000?,True,False,False,0.0,"I don't have access to specific RHEA reaction IDs in my training data, so I cannot provide the exact equation for RHEA:10000 with certainty.

RHEA is a comprehensive database of biochemical reactions that uses unique identifiers for each reaction. To find the equation for RHEA:10000, you would need to:

1. Visit the RHEA database directly at https://www.rhea-db.org/
2. Search for the reaction ID ""10000""
3. View the complete reaction equation with substrates, products, and stoichiometry

I apologize that I cannot provide the specific equation you're looking for without access to the database.",,5.191309928894043,53,152,True,False,0.4,"The equation for Rhea reaction **RHEA:10000** is:

**H₂O + pentanamide = NH₄⁺ + pentanoate**

This reaction represents the hydrolysis of pentanamide (also known as valeramide) in the presence of water to produce ammonium ion and pentanoate (valerate).",,13.675281047821045,9,255,546,52654,mcp__togomcp__run_sparql,"[{""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""rhea"", ""sparql_query"": ""\nPREFIX rh: <http://rdf.rhea-db.org/>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT ?equation\nWHERE {\n  rh:10000 rh:equation ?equation .\n}\n""}}]",CRITICAL,Pentanamide + H2O = pentanoate + NH4+ (amidase reaction),"SIMPLE QUERY - Straightforward reaction lookup.

Method: Direct SPARQL lookup of rhea:equation for RHEA:10000

Demonstrates when basic property lookups suffice.

Verified in rhea_exploration.md simple queries section."
